Výsledky vyhledávání - "Amalia Pérez Gil"

Akademický článek

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Autor: Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, Manuel Galán-Gutiérrez

Publikováno v: Life, Vol 12, Iss 11, p 1883 (2022)

Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical

Externí odkaz: https://doaj.org/article/1a9fd6d5f9224841aa9efe41d2646a74

Zobrazit plný text záznamu

Akademický článek

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

Autor: Ricardo Ruiz-Villaverde, Fiorella Vasquez-Chinchay, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Pérez-Gil, Manuel Galán-Gutiérrez

Publikováno v: Life, Vol 12, Iss 9, p 1412 (2022)

A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasi

Externí odkaz: https://doaj.org/article/168265c2256b44b0aeaabfef636ce2a0

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Interstitial granulomatous dermatitis due to a rare myeloproliferative neoplasia

Autor: Sandra Cases-Merida, Ana Lorente-Lavirgen, Amalia Pérez-Gil

Publikováno v: Indian Journal of Dermatology, Vol 63, Iss 3, Pp 264-267 (2018)

Interstitial granulomatous dermatitis (IGD) was first described in 1993 by Ackerman as a cutaneous reactive disease in patients with arthritis. Since then, numerous cases associated with different hematological and rheumatic disorders have been repor

Externí odkaz: https://doaj.org/article/850dad43c8eb41718d0b76211245fd1f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients

Autor: Isaac Almendros, Miguel Ángel Martínez-García, Francisco Campos-Rodríguez, Erica Riveiro-Falkenbach, José L. Rodríguez-Peralto, Eduardo Nagore, Antonio Martorell-Calatayud, Luis Hernández Blasco, Jose Bañuls Roca, Eusebi Chiner Vives, Alicia Sánchez-de-la-Torre, Jorge Abad-Capa, Josep Maria Montserrat, Amalia Pérez-Gil, Valentín Cabriada-Nuño, Irene Cano-Pumarega, Jaime Corral-Peñafiel, Trinidad Diaz-Cambriles, Olga Mediano, Joan Dalmau-Arias, Ramon Farré, David Gozal, On Behalf of the Spanish Sleep Network, Elidia Molina Herrera, Rosa M. García Martín, Maria Niveiro de Jaime, Sara Moreno, Ferran Barbé Ilia, Manuel Sánchez de la Torre, Esther de Eusebio, Pedro Landete, Manuel Moragón Gordon, Eva Arias, Fernando Masa, Carlos González Herrada, Cristina Carrera, Aida Muñoz Ferrer, Aram Boada, Ana Fortuna, Mercé Mayos, Jesús Gardeazabal García

Publikováno v: Frontiers in Neurology, Vol 9 (2018)

Epidemiological associations linking between obstructive sleep apnea and poorer solid malignant tumor outcomes have recently emerged. Putative pathways proposed to explain that these associations have included enhanced hypoxia inducible factor (HIF)-

Externí odkaz: https://doaj.org/article/2d7e1908801e4e8897eb6f47bffcf587

Zobrazit plný text záznamu

Guselkumab dosing interval optimization in adult patients with moderate‐to‐severe psoriasis switching from ustekinumab

Autor: Ricardo Ruiz‐Villaverde, Fiorella Vasquez Chinchay, Lourdes Rodriguez‐Fernandez‐Freire, Jose C. Armario‐Hita, Amalia Pérez‐Gil, Manuel Galán‐Gutiérrez

Publikováno v: Dermatologic Therapy. 35

Psoriasis (PSO) is an inflammatory disease that emerges as a dysregulation of the interleukin 23 (IL23)/Th17 axis. There are many biologic alternatives to treat PSO that are administered monthly, every 2 months and every 3 months. Guselkumab (GUS) is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7654b48c4abc763981ab1e211e9ed72d
https://doi.org/10.1111/dth.15835

Zobrazit plný text záznamu

Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

Autor: Ricardo Ruiz‐Villaverde, Lourdes Rodriguez‐Fernandez‐Freire, Jose Carlos Armario‐Hita, Amalia Pérez‐Gil, Fiorella Vasquez Chinchay, Manuel Galán‐Gutiérrez

The IL23/Th17 axis plays a strategic role in psoriasis (PSO). Guselkumab (GUS) is a selective inhibitor of the IL23p19 subunit. Its introduction has managed to increase the levels of efficacy, safety and survival in PSO. In real clinical practice, pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf76cbc68be58ff598376215c2505b23
https://hdl.handle.net/10668/19939

Zobrazit plný text záznamu

Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry

Publikováno v: EUROPEAN JOURNAL OF CANCER
r-FISABIO. Repositorio Institucional de Producción Científica
instname
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Dipòsit Digital de la UB
Universidad de Barcelona
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

[Background] Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.
[Objectives] To evaluate the response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3695ef88520e05d5d22333cfb6b048f
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14182

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání